The ATP6V0D1 antibody targets the ATP6V0D1 protein, a critical subunit of the vacuolar-type H+-translocating ATPase (V-ATPase) complex. V-ATPases are multisubunit proton pumps responsible for acidifying intracellular organelles, such as lysosomes, endosomes, and secretory vesicles, which is essential for processes like protein degradation, membrane trafficking, and cellular signaling. ATP6V0D1. specifically, is a component of the V0 domain of the V-ATPase, which forms the transmembrane proton channel. It plays a role in assembly, stability, and activity of the V-ATPase complex. Research on ATP6V0D1 has linked it to diverse physiological and pathological processes, including autophagy, osteoclast function, and tumor metastasis. Dysregulation of ATP6V0D1 expression or activity is implicated in diseases such as cancer, neurodegenerative disorders, and lysosomal storage diseases. Antibodies against ATP6V0D1 are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to study its expression, localization, and interactions in cells and tissues. These tools help elucidate its role in organelle acidification, pH homeostasis, and disease mechanisms. Commercial ATP6V0D1 antibodies are typically generated using recombinant protein fragments or synthetic peptides as immunogens, with validation steps (e.g., knockout controls) ensuring specificity. Such antibodies are vital for advancing studies on cellular metabolism, membrane transport, and therapeutic targeting of V-ATPase-related disorders.